Navigation Links
GeoVax Phase 2a Clinical Trial Completes Enrollment
Date:10/3/2011

ATLANTA, Oct. 3, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today the completion of enrollment for a Phase 2a clinical trial testing its HIV/AIDS vaccine. The vaccine is being developed for use in uninfected people to prevent infection should they be exposed to the virus. The trial, designated HVTN 205, is being conducted by the HIV Vaccines Trials Network (HVTN), which is funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. A total of 299 participants are enrolled in HVTN 205.

GeoVax also announced the unblinding of data for neutralizing antibody (Ab) responses in part 1 of HVTN 205 – showing elicitation of unexpectedly high response rates of neutralizing antibody for tier 2 isolates of HIV-1.  Of 46 tested vaccine recipients, 50% responded with neutralizing activity for tier 2 clade B isolate RHPA; and 26% with neutralizing antibody for tier 2 clade B isolate SC22.3C2. Neutralizing antibodies can block virus from infecting cells by binding to regions of the virus that mediate entry into cells. The elicitation of neutralizing antibody for tier 2 viruses is an important result because tier 2 viruses represent viruses that undergo the most frequent transmission from an infected person to an uninfected person. A new highly sensitive test was used for conducting neutralization tests, which were done at the HVTN laboratories at Duke University.

"Elicitation of neutralizing antibody is a much sought goal for an HIV/AIDS vaccine," said Harriet Robinson, Ph.D., Chief Scientific Officer of GeoVax. "The field has been trying to achieve this goal by re-engineering the HIV envelope protein that mediates entry into cells. Our vaccines use natural forms of the HIV envelope to raise antibody. We are extremely pleased that our natural f
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
2. GeoVax Labs, Inc. Announces Second Quarter Financial Results
3. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
4. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
5. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
6. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
7. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
8. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
9. GeoVax Labs Engages The Investor Relations Group
10. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results
11. GeoVax Labs, Inc. Plans Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... former senior vice president and corporate controller, has been ... effective immediately, replacing Peggy Mulligan, former chief financial officer, ... other interests.  The Company has initiated a search to ...
... (Nasdaq: STXS ) announced today that the Company ... which includes a $30 million revolving facility that matures on ... matures on December 31, 2013.  The new facility was led ... that was scheduled to mature in March 2011. ...
Cached Medicine Technology:Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO 2Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO 3Stereotaxis Completes $40 Million Credit Facility 2Stereotaxis Completes $40 Million Credit Facility 3
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2
... same odds for condition, regardless of screening , , SUNDAY, June 8 ... less risk than previously believed of having silent myocardial ischemia, a ... study. , In fact, all adults aged 55 to ... a cardiac condition whether they are screened for the problem or ...
... 7, 2008 The International Diabetes Federation (IDF) Task ... research demonstrates that type 2 diabetes and obstructive sleep ... have significant implications on public health and on individuals. ... and sleep experts who examined the impacts of untreated ...
... Organization, Carolyn,s Compassionate Children gives cancer, ... of attending college, BOSTON, June 7 ... and cancer survivor Leanna,Elizalde with a $2,500 Survivorship ... School,s graduation ceremony Saturday. Alex Oden, 20, a,two-time ...
... Distributed, Flexible, Redundant, Patient-Specific Intra-Venous, (IV) Automation Robot for Non-Hazardous ... Satellite Pharmacies, and Even ... Patient Care Workplaces, ... leader in the robotic automation of patient-specific IV,Admixtures today announced ...
... 2 diabetes risk but could suggest its causes ... identified a gene that regulates glucose levels but does ... their finding may help improve understanding of the underlying ... diagnostic of diabetes. This finding demonstrates there are gene ...
... Becomes "Susan G. Komen GLOBAL Race for the ... Mall was,passionately pink this morning, as nearly 50,000 ... the 19th annual Susan,G. Komen National Race for ... fund breast cancer research and community health programs ...
Cached Medicine News:Health News:Older Diabetics' Risk of Cardiac Ischemia Lower Than Thought 2Health News:IDF urges health care providers to address the relationship between type 2 diabetes and sleep apnea 2Health News:Nonprofit Organization Dedicated to Helping Young Adult Cancer Survivors Raises $4500 for Leanna Elizalde 2Health News:Health Robotics Announces IV Station (TM Pending) a Centrally-Controlled, 2Health News:Health Robotics Announces IV Station (TM Pending) a Centrally-Controlled, 3Health News:Scientists ID Gene Regulating Blood Glucose Levels 2Health News:19th Annual Susan G. Komen National Race for the Cure(R) Draws Nearly 50,000 Participants, Celebrities; Brings Record Funds to National Capital Area 2Health News:19th Annual Susan G. Komen National Race for the Cure(R) Draws Nearly 50,000 Participants, Celebrities; Brings Record Funds to National Capital Area 3
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: